- Home
- CVM vs ENVB Comparison
CVM vs ENVB Comparison
Compare CVM & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- ENVB
- Stock Information
- Founded
- CVM 1983
- ENVB 1994
- Country
- CVM United States
- ENVB United States
- Employees
- CVM N/A
- ENVB 6
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- CVM Health Care
- ENVB Health Care
- Exchange
- CVM Nasdaq
- ENVB Nasdaq
- Market Cap
- CVM N/A
- ENVB 2.9M
- IPO Year
- CVM 1987
- ENVB N/A
- Fundamental
- Price
- CVM $0.29
- ENVB $1.38
- Analyst Decision
- CVM
- ENVB Strong Buy
- Analyst Count
- CVM 0
- ENVB 1
- Target Price
- CVM N/A
- ENVB $10.00
- AVG Volume (30 Days)
- CVM 1.5M
- ENVB 67.9K
- Earning Date
- CVM 05-15-2025
- ENVB 05-14-2025
- Dividend Yield
- CVM N/A
- ENVB N/A
- EPS Growth
- CVM N/A
- ENVB N/A
- EPS
- CVM N/A
- ENVB N/A
- Revenue
- CVM N/A
- ENVB N/A
- Revenue This Year
- CVM N/A
- ENVB N/A
- Revenue Next Year
- CVM N/A
- ENVB N/A
- P/E Ratio
- CVM N/A
- ENVB N/A
- Revenue Growth
- CVM N/A
- ENVB N/A
- 52 Week Low
- CVM $0.18
- ENVB $1.01
- 52 Week High
- CVM $2.39
- ENVB $231.75
- Technical
- Relative Strength Index (RSI)
- CVM 55.12
- ENVB 30.68
- Support Level
- CVM $0.18
- ENVB $1.14
- Resistance Level
- CVM $0.28
- ENVB $1.42
- Average True Range (ATR)
- CVM 0.04
- ENVB 0.11
- MACD
- CVM 0.01
- ENVB 0.32
- Stochastic Oscillator
- CVM 78.86
- ENVB 90.24
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.